Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure

Launched by CENTRO CARDIOLOGICO MONZINO · Oct 20, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on using advanced technology, specifically artificial intelligence (AI) and smart wearable devices, to help detect early signs of worsening heart failure. Heart failure is a serious condition where the heart doesn't pump blood as well as it should, and unfortunately, many patients experience repeated hospital visits due to the gradual decline in their health. The goal of this trial is to create a tool that can monitor patients with chronic heart failure and identify when their condition is getting worse, so that doctors can intervene early. By catching these changes sooner, we hope to improve patients' quality of life and reduce the time they spend in the hospital.

To be eligible for the trial, participants should be between the ages of 65 and 74 and have specific symptoms or signs of heart failure, as well as a certain level of heart function measured by an ultrasound of the heart. However, those with more severe heart failure or certain other medical conditions will not be included in the study. Participants will wear a special vest that collects health data, allowing researchers to better understand how to predict worsening heart failure. This could lead to better care and outcomes for patients. Please note that the trial is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Presence of symptoms and/or signs of HF
• • left ventricular ejection fraction (LVEF) ≤40%. LVEF values will be obtained by determining the reduced LV systolic function, by transthoracic echocardiographic assessment as recommended by European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography position paper.
• • NYHA functional classes II-III).
• Exclusion Criteria:
• • NYHA functional class IV,
• • Candidates for left-ventricular assist device (LVAD) or heart transplant, as per latest definition of Heart Failure Association of the ESC.
• • Recent acute coronary syndrome within 1-year prior to the date of potential enrollment,
• • Indirect echocardiographic evidence of significantly elevated pulmonary pressures
• • Clinically relevant pulmonary hypertension
• • non-adherence to optimal medical treatment for CHF